Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Brookings Institution, the most common co-covered peer. At 8, the average consequence score sits above the same-window beat average of 6.
Last mentioned: Mar 19, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Brookings Institution, the most common co-covered peer. At 8, the average consequence score sits above the same-window beat average of 6. They are better corroborated than the beat average, carrying 3 original sources each against 2.6 for the same window. Neal Dunn appears in 1 tracked Biotech story from March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Neal Dunn. Shared-story counts are live from our verified record — not editorial picks.
The House Select Committee on China has warned that Beijing is executing a long-term strategy to dominate the global pharmaceutical market, mirroring its tactics in the rare earth and EV sectors. With China's drug and medical device revenue projected to reach $2.1 trillion by 2030, US officials are calling for urgent action to reduce reliance on Chinese-made active pharmaceutical ingredients.
Neal Dunn is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
